Cover Image
市場調查報告書

再生醫療:全球市場趨勢·估計·預測 (2013∼2019年)

Regenerative Medicine: Global Trends, Estimates and Forecasts, 2013-2019

出版商 Axis Research Mind 商品編碼 328704
出版日期 內容資訊 英文 379 Pages; 99 Tables/Charts
商品交期: 最快1-2個工作天內
價格
Back to Top
再生醫療:全球市場趨勢·估計·預測 (2013∼2019年) Regenerative Medicine: Global Trends, Estimates and Forecasts, 2013-2019
出版日期: 2015年04月21日 內容資訊: 英文 379 Pages; 99 Tables/Charts
簡介

全球再生醫療市場預測在2017年將達到247億美元的規模。尤其是整形外科用再生醫療更將在同一年達到103億美金的規模,此外2013∼2019年的年複合成長率(CAGR) 預計將為12.2%。皮膚·外皮相關和泌尿系統相關佔整體市場的25.97% (2016年)。就地區別來看,預計亞太地區的年複合成長率(CAGR) 將達到18.1% (2013∼2019年)。

本報告提供全球的再生醫療市場最新趨勢與未來展望相關分析,提供您再生醫療的概要和到目前為止的技術進步,各部門·各地區的市場規模預測 (今後7年份),今後主要的與成長領域,各地區市場詳細趨勢,主要企業簡介與競爭力,再加上今後的投資策略等估計·考察。

第1章 分析的焦點

  • 簡介
    • 再生醫療:概要
    • 組織工程 (Engineering Co )
    • 幹細胞
    • 針對再生醫療的生物學替代物
    • 再生醫療和各種適應症
      • 皮膚/外皮
      • 整形外科的再生醫療的發展
      • 心臟再生
      • 神經性障礙用再生治療藥
      • 腎臟再生
      • 組織工程的基礎
      • 糖尿病與再生醫療
      • 老年癡呆症與再生醫療
      • 自體免疫疾病與再生醫療
      • 眼科疾病與再生醫療預測
    • 再生醫療的今後趨勢
    • 政府提供的資金
    • 美國的醫療統計
  • 再生醫療:市場概要
    • 南北美洲
    • 歐洲
    • 亞太地區
    • 其他的國家 (ROW)

第2章 市場分析

  • 再生醫療:市場明細
  • 成長率分析
  • 投資的焦點

第3章 產業概況

  • 產業活動
    • 企業合併·收購 (M&A)/契約/專利給予/合資企業/市場趨勢等
  • 主要企業簡介
    • 南北美洲
    • 歐洲
    • 亞太地區
    • 其他的國家 (ROW)

第4章 產業·企業的資料庫

第5章 附錄

圖表一覽

目錄
Product Code: ARMMR208

Global Regenerative Medicine market is estimated to reach US$24.7 billion by 2017. Regenerative Medicine in Orthopedics market is projected to reach US$10.3 billion by 2017, growing at a CAGR of 12.2% for the analysis period 2013-2019 respectively. Skin/Integumentary and Urology together account for approximately 25.97% (2016) of the market are expected to support the Regenerative Medicine Industry going forward. Geographical analysis for Regenerative Medicine in Cardiology shows that the highest Compounded Annual Growth Rate (CAGR) of 18.1% is anticipated from Asia-Pacific region during the analysis period 2013-2019.

Report Focus:

The report 'Regenerative Medicine - Global Trends, Estimates and Forecasts, 2013-2019 ' reviews the latest trends in regenerative medicine with a perceptive attempt to disclose the near-future growth prospects. An in-depth analysis on a geographic basis provides strategic business intelligence for healthcare sector investments. The study reveals profitable investment strategies for market start-ups, pharmaceutical/biotechnology companies, laboratories, Contract/Clinical/Commercial Research Organizations (CROs), government/academic organizations, consulting firms, database buyers and many more in preferred locations. The report primarily focuses on:

  • Emerging Market Trends
  • Advancements in the Technological Space
  • Market Demand of The Segments (By-Region)
  • Key Growth Areas and Market Size
  • Region-Wise Demand Factor
  • Key Competitors Edge
  • Investment Strategies

Estimates are based on online surveys using customized questionnaires by our research team. Besides information from government databases, company websites, press releases & published research reports are also used for estimates.

The analysis primarily deals by therapeutic area and biological substitutes. Further, the subdivided categories include:

Regenerative Medicine - Segmentation

  • Therapeutic Area
    • Orthopedics
    • Skin/Integumentary
    • Cardiology
    • Neurology
    • Urology
    • Other
  • Biological Substitutes
    • Cells and Biomaterials
    • Biomolecules
    • Manufacturing Factors and
    • Other

The period considered for the regenerative medicine market analysis is 2013-2019. The region wise distribution of the market consists of The Americas (USA, Brazil, Canada and Rest of The Americas), Europe (Germany, United Kingdom, France, Switzerland, Spain, The Netherlands, Russia and Rest of Europe), Asia-Pacific (Japan, South Korea, Australia,

China, India and Rest of Asia-Pacific) and Rest of World (Africa and Middle East). The market growth rate in the major economies such as the U.S., Japan, China etc. are estimated individually.

More than 600 market players are identified in regenerative medicine industry out of which 21 key companies that project improved market activities in the near future are profiled. The report consists of 99 data charts describing the market shares, sales forecasts and growth prospects. Moreover, key strategic activities in the market including mergers/acquisitions, collaborations/partnerships, product launches/developments are discussed.

Table of Contents

I. REPORT FOCUS

I. INTRODUCTION

A. REGENERATIVE MEDICINE - IN BRIEF

  • HISTORY OF ORGAN ENGINEERING

THE METHODOLOGY OF REGENERATIVE MEDICINE

  • 1) HUMAN SUBSTANCES
  • 2) CELLS AND TISSUES
  • 3) EMBRYONIC STEM CELLS
    • NUCLEAR TRANSPLANTATION
    • OPPOSITION TO USE OF EMBRYONIC STEM CELLS AND NUCLEAR TRANSPLANTATION
  • 4) NOVEL MATERIALS
  • THE COMPETENT ASSOCIATION BETWEEN REGENERATIVE MEDICATION AND PHYSICAL THERAPEUTICS
  • CLINICAL TOOLS AND SYNTHETIC ORGANS
  • MATERIAL TREATMENTS AND BIO SUBSTANCES
  • CELLULAR TREATMENTS
  • PREVALENT HURDLES IN THE PROGRESS OF CELLULAR THERAPIES
  • BARRIERS
  • SKELETAL MUSCLE
  • CARDIAC
  • BONE
  • OBJECTIVE MEASURES TOWARD REGENERATIVE REHABILITATION
    • CONCLUSIONS

B. TISSUE ENGINEERING

  • REGENERATIVE MEDICINE AND TISSUE ENGINEERING
  • HISTORY OF TISSUE ENGINEERING
  • METHODS OF TISSUE ENGINEERING
  • TISSUE ENGINEERING AND REGENERATIVE MEDICINE IN THE CURRENT MEDICAL ORDER
  • NIH SPONSORED RESEARCH IN TISSUE ENGINEERING AND REGENERATIVE MEDICINE
    • INFLUENCING STEM CELLS BY MANIPULATING THEIR ENVIRONMENT
    • TRANSPLANTING HUMAN LIVERS IN MICE
    • ENGINEERING MATURE BONE STEM CELLS
    • USING LATTICES TO HELP ENGINEERED TISSUE SURVIVE
    • POSSIBLE TREATMENT OPTION FOR WORN OUT/INJURED KNEES
    • RE-GROWING A NEW KIDNEY
  • TISSUE ENGINEERING AND BIOMATERIALS
    • CELL AND TISSUE BANKING STANDARDS AND ACCREDITATION

C. STEM CELLS

  • INTRODUCTION TO STEM CELLS
  • HISTORY OF STEM CELLS
  • TYPES OF STEM CELLS
  • 1) EMBRYONIC STEM (ES) CELLS AND EPIBLAST STEM CELLS
  • 2) NON-EMBRYONIC STEM CELLS (NON-ESC)
    • TISSUE STEM CELLS
    • INDUCED PLURIPOTENT STEM (IPS) CELLS
  • REGENERATIVE MEDICINE AND STEM CELLS
  • THE MICROENVIRONMENT OF THE STEM CELL
  • EMBRYONIC STEM CELLS A MORE DETAILED LOOK
  • BLASTOCYST AS A SOURCE OF STEM CELLS LEGAL ISSUES
  • NON-EMBRYONIC STEM CELLS
  • 1) AMNIOTIC FLUID DERIVED STEM CELLS
  • 2) CORD BLOOD STEM CELLS
    • TYPE-1 DIABETES
    • CARDIOVASCULAR CONDITIONS
    • CENTRAL NERVOUS SYSTEM
  • 3) BONE-MARROW DERIVED STROMAL STEM CELLS
  • 4) IN-VITRO MSC DIFFERENTIATION
  • 5) STEM CELLS DERIVED FROM FAT TISSUE
  • 6) MONOCYTES
  • STEM CELL TREATMENTS WHY HAVEN'T THEY GAINED WIDESPREAD POPULARITY?
  • APPLICATIONS OF STEM CELLS IN TREATMENT OF VARIOUS DISEASES AND CONDITIONS
  • A) BONE
  • I) BONE DEFECTS
  • II) FRACTURE NON-UNION
  • III) OSTEOGENESIS IMPERFECTA
  • B) CARTILAGE
  • C) CARDIAC MUSCLE
  • D) URINARY TISSUES - BLADDER
  • E) SPINAL CORD
  • CONCLUSION
  • CELL-BASED THERAPIES
  • CELLS DEVELOPED TODAY ARE FUTURE THERAPIES

D. BIOLOGICAL SUBSTITUTES FOR REGENERATIVE MEDICINE

  • AREAS IN HUMAN TISSUE CONSTRUCTION
  • BIOMATERIALS
  • CELLS
  • BIOMOLECULES
  • SAFETY AND PRESENTATION CONCERNS
  • DEVELOPMENTAL FEATURES
  • OTHER FACTORS

E. REGENERATIVE MEDICINE AND VARIOUS CONDITIONS

1. SKIN/ INTEGUMENTARY

  • SKIN-TREATMENT
  • SKIN REVIVAL
  • NERVE REVIVAL
  • SKELETAL MUSCLE REVIVAL
  • REGENERATIVE DRUGS FOR SKIN DISEASES IPS CELLS TO THE SALVAGE
  • SKIN AND CUTANEOUS CELLS AND TISSUE APPLICATIONS OPT FOR DEVELOPMENT
  • DO-US ASSOCIATION IN REGENERATIVE MEDICINE TO SUPPORT ACID ATTACK VICTIMS

2. REGENERATIVE MEDICINE'S PROGRESS IN ORTHOPEDICS

  • CONTEMPORARY NOTIONS
    • APPROACHES
    • CELLS
    • MORPHOGENETIC STIMULUS
    • SCAFFOLDS
    • MECHANICAL STIMULATION
    • ADVANCEMENT
    • BONE
  • REGENERATIVE MEDICINE IN THE BONE
  • CARTILAGE
  • OTHER ORGANS
  • A. INTERVERTEBRAL DISK
  • B. MENISCUS
  • C. LIGAMENT AND TENDON
  • GENE THERAPY STRATEGY
  • GENE THERAPY COMMERCIAL MILESTONES
    • 2013
    • 2012
    • 2010
  • VIEWPOINTS

3. CARDIAC REGENERATIVE MEDICINE

  • CARDIOVASCULAR AND REGENERATIVE MEDICINE
  • OUTLINE
  • TYPE OF CVD
  • CARDIOVASCULAR DISEASE AND REVIVAL MEDICINE
    • AASTROM
    • AMORCYTE
    • ATHERSYS INC.'S
    • CAPRICOR
    • CYTOMEDIX
    • CYTORI THERAPEUTICS
    • JUVENTAS THERAPEUTICS
    • MESOBLAST'S

4. REGENERATIVE DRUGS FOR NEUROLOGICAL DISABILITIES

  • REGENERATIVE DRUGS FOR NEUROLOGICAL DISEASES WITH THE USE OF ELECTRICAL STIMULATION
  • 1. INTRODUCTION
  • 2. ELECTRICAL STIMULUS FOR CEREBRAL INFARCTION
  • 3. LONG-TERM POTENTIATION AND NEUROGENESIS
    • CONCLUSION

5. REGENERATIVE NEPHROLOGY

  • REGENERATIVE DRUG STRATEGIES TO HEAL NEUROGENIC BLADDER
    • INTRODUCTION

6. THE ESSENTIALS OF TISSUE ENGINEERING

  • BIO-SUBSTANCES USED IN GENITOURINARY TISSUE RENOVATION
  • CELLS FOR UROGENITAL TISSUE REGENERATION TECHNOLOGIES
  • TISSUE PROGRAMMING STRATEGIES FOR BLADDER BOOST AND REPLACEMENT
  • BIOSUBSTANCES SCAFFOLDS FOR BLADDER REGENERATION
  • REGENERATIVE DRUGS FOR BLADDER USING CELL TRANSPLANTATION
    • CONCLUSION

7. DIABETES AND REGENERATIVE MEDICINE

8. ALZHEIMER'S AND REGENERATIVE MEDICINE

9. AUTOIMMUNE DISORDERS AND REGENERATIVE MEDICINE

10. REGENERATIVE MEDICINE IN OPHTHALMOLOGY - PROSPECT

  • PREAMBLE
  • CELLULAR TREATMENTS
  • RESULTS - ADVANTAGES
  • LIMITATIONS
  • BIO-SUBSTANCES IN THE CORNEA
    • CORNEAL REPLACEMENTS ARE A POSSIBLE OPTION THAT NEEDS TO ADDRESS
    • BIO-SUBSTANCES NEED TO BE
    • OVERVIEW OF KPRO
  • EXERCISE ENGINEERING STRUCTURE TO CORNEAL DISEASE

F. REGENERATIVE MEDICINE THE FUTURE TRENDS

  • ALTERED DEMOGRAPHICS CREATE GREATER BURDEN OF CHRONIC DISEASE
  • AN EMERGING INDUSTRY
  • OBTAINING REGULATORY NORMS IN PLACE
  • FDA PROCEDURES
  • CROSS-AGENCY MANAGEMENT
  • REGULATORY DISCIPLINE

G. GOVERNMENT FUNDING

  • PUBLIC AND PRIVATE INVESTMENT EXCEEDS $1 BILLION

H. US HEALTHCARE STATISTICS

  • THE COST IMPACT OF AN AGING POPULATION
  • POTENTIAL ECONOMIC IMPACT OF REGENERATIVE MEDICINE

II. REGENERATIVE MEDICINE - MARKET BRIEFING

  • THE AMERICAS
  • EUROPE
  • ASIA-PACIFIC
  • REST OF WORLD

II. MARKET ANALYSIS

  • REGENERATIVE MEDICINE - INDUSTRY SNAPSHOT

A. REGENERATIVE MEDICINE - SEGMENTATION

  • REGENERATIVE MEDICINE - GLOBAL
  • REGENERATIVE MEDICINE - BY GEOGRAPHY
    • THE AMERICAS
    • EUROPE
    • ASIA-PACIFIC
    • REST OF WORLD
  • REGENERATIVE MEDICINE - BY THERAPEUTIC AREA
  • REGENERATIVE MEDICINE - THERAPEUTIC AREA - BY GEOGRAPHY
  • ORTHOPEDICS
    • THE AMERICAS
    • EUROPE
    • ASIA-PACIFIC
    • REST OF WORLD
  • SKIN/INTEGUMENTARY
    • THE AMERICAS
    • EUROPE
    • ASIA-PACIFIC
    • REST OF WORLD
  • CARDIOLOGY
    • THE AMERICAS
    • EUROPE
    • ASIA-PACIFIC
    • REST OF WORLD
  • NEUROLOGY
    • THE AMERICAS
    • EUROPE
    • ASIA-PACIFIC
    • REST OF WORLD
  • UROLOGY
    • THE AMERICAS
    • EUROPE
    • ASIA-PACIFIC
    • REST OF WORLD
  • OTHER THERAPEUTIC AREAS (REGENERATIVE MEDICINE)
    • THE AMERICAS
    • EUROPE
    • ASIA-PACIFIC
    • REST OF WORLD
  • REGENERATIVE MEDICINE - BIOLOGICAL SUBSTITUTES - BY TYPE

B. GROWTH RATE ANALYSIS

  • A. REGENERATIVE MEDICINE MARKET GROWTH RATES - BY GEOGRAPHY
  • B. REGENERATIVE MEDICINE MARKET - BY THERAPEUTIC AREA GROWTH RATES

C. INVESTMENT FOCUS

III. INDUSTRY OVERVIEW

A. INDUSTRY ACTIVITIES

  • MERGERS/ACQUISITIONS/AGREEMENTS/PATENTS GRANTS/JOINT VENTURES/TRENDS, ETC......
    • KITE PHARMA ESTABLISHES MANUFACTURING CAPABILITIES TO SUPPORT DEVELOPMENT AND COMMERCIALIZATION OF CAR AND TCR CANCER IMMUNOTHERAPY PRODUCTS
    • SIGNIFICANT FINDINGS IN U.S. NATIONAL INSTITUTES OF HEALTH'S TRIAL OF PLURISTEM'S PLX-R18 CELLS FOR TREATMENT OF ACUTE RADIATION SYNDROME
    • NOVASEP SELECTED TO COMMERCIALLY BIOMANUFACTURE CELLADON'S MYDICAR API
    • CYTORI BEGINS ENROLLMENT IN ACT-OA: US PHASE II TRIAL FOR KNEE OSTEOARTHRITIS
    • CAN 3-D PRINTING OF LIVING TISSUE SPEED UP DRUG DEVELOPMENT?
    • TEAM CREATES NEW APPROACH TO GENE THERAPY
    • CELLULAR DYNAMICS' ICELL HEPATOCYTES ENABLE MALARIA-IN-A-DISH STUDIES
    • CESCA THERAPEUTICS ANNOUNCES APPROVAL OF ITS MARROWXPRESSTM SYSTEM IN INDIA
    • VOYAGER THERAPEUTICS & GENZYME ANNOUNCE MAJOR STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE NOVEL AAV GENE THERAPIES FOR PATIENTS WITH CNS DISORDERS
    • VALEANT PHARMACEUTICALS ANNOUNCES EXPIRATION OF BID DEADLINE IN CONNECTION WITH AGREEMENT TO ACQUIRE ASSETS FROM DENDREON
    • 3-D PRINTERS TAKE CENTER STAGE IN JAPAN'S REGENERATIVE MEDICINE
    • CYNATA PARTNERS WITH UWA CENTRE FOR CELL THERAPY AND REGENERATIVE MEDICINE
    • ASTRAZENECA ANNOUNCES COLLABORATIONS TO USE CRISPR TECHNOLOGY FOR GENOME EDITING ACROSS ITS DRUG DISCOVERY PLATFORM
    • AVITA MEDICAL ANNOUNCES FIRST PATIENT ENROLMENT IN US PIVOTAL STUDY OF RECELL®
    • USING 3D PRINTING, MAKERBOT AND FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH CREATE CARTILAGE TO REPAIR TRACHEAL DAMAGE
    • SISTEMIC AND ROSLIN CELLS ANNOUNCE GROUND-BREAKING COLLABORATION AGREEMENT ON IPSC CHARACTERISATION AS PART OF MAJOR EUROPEAN INNOVATIVE MEDICINES INITIATIVE PROGRAMME
    • ATHERSYS AND CELL THERAPY CATAPULT ANNOUNCE GRANT TO SUPPORT CLINICAL DEVELOPMENT OF STEM CELL THERAPY FOR SEVERE ACUTE RESPIRATORY CONDITION
    • CELL THERAPY CATAPULT AND TRAKCEL TO COLLABORATE ON RESEARCH PROJECT
    • NEOSTEM AND INVETECH ANNOUNCE AGREEMENT TO DEVELOP CLOSED PROCESSING SYSTEM FOR CELL THERAPY MANUFACTURING
    • NUO THERAPEUTICS AND ROHTO PHARMACEUTICAL CO. SIGN EXCLUSIVE LICENSING AND DISTRIBUTION AGREEMENT FOR AURIX IN JAPAN
    • RESEARCHERS GROW FUNCTIONAL TISSUE-ENGINEERED INTESTINE FROM HUMAN CELLS
    • HART AND MAYO CLINIC COLLABORATE ON REGENERATED TRACHEA, ESOPHAGUS AND HEART VALVE
    • NOVARTIS COLLABORATES WITH INTELLIA THERAPEUTICS AND CARIBOU BIOSCIENCES TO EXPLORE MAKING MEDICINES AND DRUG DISCOVERY TOOLS WITH CRISPR GENOME EDITING TECHNOLOGY
    • TXCELL AND FERRING COLLABORATION WITH LEAD PRODUCT OVASAVE
    • ORTHOCELL AND BONESUPPORT ENTER INTO BONE REPAIR PARTNERSHIP
    • INVIVO THERAPEUTICS ANNOUNCES FDA APPROVAL TO EXPEDITE ENROLLMENT FOR ONGOING PILOT TRIAL
    • BIOTIME, INC. SUBSIDIARY ONCOCYTE CORPORATION COMPLETES INITIAL ENROLLMENT OF CLINICAL STUDY OF URINE-BASED BLADDER CANCER DIAGNOSTIC
    • HERAEUS MEDICAL LICENSES PLATFORM POLYMER TECHNOLOGY TO FURTHER ITS REGENERATIVE ORTHOPEDICS STRATEGY
    • VOYAGER THERAPEUTICS AND MASSBIOLOGICS ANNOUNCE STRATEGIC COLLABORATION FOR VIRAL VECTOR MANUFACTURING
    • NYSCF AND THE CMTA ENTER COLLABORATION TO ADVANCE NEUROPATHIES RESEARCH
    • LEADING BONE REPAIR COMPANY BONESUPPORT AND REGENERATIVE MEDICINE COMPANY ORTHOCELL LTD ANNOUNCE A HEADS OF AGREEMENT
    • PFIZER EXPANDS RARE DISEASE RESEARCH WITH ESTABLISHMENT OF GENE THERAPY PLATFORM
    • ESTABLISHMENT OF GENE THERAPY RESEARCH IN PFIZER RARE DISEASE
    • GE HEALTHCARE LIFE SCIENCES LICENSES CRISPR GENE ENGINEERING TECHNOLOGY PATENTS FROM BROAD INSTITUTE
    • ORGANOVO COLLABORATES WITH YALE TEAM TO DEVELOP 3-D ORGAN TISSUES FOR SURGICAL TRANSPLANTATION RESEARCH
    • PLURISTEM GRANTED PATENT IN SINGAPORE FOR ITS 3D CELL EXPANSION TECHNOLOGY
    • STEM CELL AGENCY & ISRAEL ANNOUNCE INTERNATIONAL COLLABORATION TO ADVANCE STEM CELL RESEARCH
    • HARVARD APPARATUS REGENERATIVE TECHNOLOGY NO LONGER SUPPORTING STUDIES IN RUSSIA; WILL CONTINUE FOCUS ON PRECLINICAL PROCESSES IN THE U.S. AND EU
    • JAPANESE LEGISLATION TAKES EFFECT FOR EXPEDITED APPROVALS OF REGENERATIVE MEDICAL PRODUCTS
    • AASTROM BIOSCIENCES CHANGES NAME TO VERICEL CORPORATION
    • JUNO T CELL THERAPY FOR LEUKEMIA GRANTED FDA BREAKTHROUGH THERAPY DESIGNATION
    • OCATA THERAPEUTICS RECEIVES ADVANCED THERAPY MEDICINAL PRODUCT DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY
    • TRANSPOSAGEN BIOPHARMACEUTICALS ENTERS INTO RESEARCH COLLABORATION AND WORLDWIDE LICENSE AGREEMENT WITH JANSSEN FOR ALLOGENEIC CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES
    • POLAND AND CALIFORNIA ANNOUNCE INTERNATIONAL COLLABORATION TO ADVANCE STEM CELL RESEARCH TOWARD CURES
    • ADVANCED CELL TECHNOLOGY CHANGES NAME TO OCATA THERAPEUTICS
    • CYTOMEDIX ANNOUNCES CORPORATE NAME CHANGE TO NUO THERAPEUTICS, INC.
    • CARDIO3 BIOSCIENCES ACQUIRES CORQUEST MEDICAL INC.
    • UNIVERSITY AND GSK COLLABORATION AIMS TO TACKLE MYELIN REGENERATION
    • THE NEW YORK STEM CELL FOUNDATION RESEARCH INSTITUTE ANNOUNCES LARGEST-EVER STEM CELL REPOSITORY
    • TERUMO BCT AND ONEBLOOD PARTNER IN A TREATMENT USE PROGRAM OF AN INVESTIGATIONAL DEVICE TO HELP IMPROVE BLOOD SUPPLY SAFETY
    • ROOSTERBIO SELECTS BIOLIFE SOLUTIONS CRYOSTOR® TO COMMERCIALIZE HUMAN BONE MARROW-DERIVED STEM CELLS
    • PLURISTEM ADVANCES ITS SECOND MAJOR CELL THERAPY PRODUCT LINE FROM DEVELOPMENT TO LARGE-SCALE MANUFACTURING
    • CYTORI PATENTS AUTOMATED TISSUE PROCESSING DEVICE IN JAPAN AND TREATMENTS FOR WOUND HEALING IN CHINA
    • OSIRIS AND ARTHREX ANNOUNCE AN EXCLUSIVE PARTNERSHIP FOR THE COMMERCIALIZATION AND DEVELOPMENT OF CARTIFORM
    • THERMO FISHER SCIENTIFIC ANNOUNCES ITS ION PGM DX NEXT GENERATION SEQUENCING SYSTEM IS NOW CE-MARKED FOR IN VITRO DIAGNOSTIC (IVD) USE
    • ACT ANNOUNCES POSITIVE RESULTS FROM TWO CLINICAL TRIALS PUBLISHED IN THE LANCET USING DIFFERENTIATED STEM CELL-DERIVED RETINAL PIGMENT EPITHELIUM (RPE) CELLS FOR THE TREATMENT OF MACULAR DEGENERATION
    • PROMETHERA BIOSCIENCES RECEIVES APPROVAL IN BELGIUM TO ENROLL PATIENTS IN THE IMMINENT HEP002 PHASE IIB/III CLINICAL TRIAL
    • THE NATIONAL STEM CELL FOUNDATION PARTNERS WITH THE ORTHOPAEDIC RESEARCH AND EDUCATION FOUNDATION ON STEM CELL RESEARCH FOR THE REGENERATION AND REPAIR OF MUSCULOSKELETAL TISSUES
    • CARDIO3 BIOSCIENCES RECEIVES AUTHORIZATION TO ENROLL PATIENTS IN SWITZERLAND IN ITS PHASE III CLINICAL TRIAL CHART-1
    • SMITH & NEPHEW ANNOUNCES TOP-LINE RESULTS OF HP802-247 PHASE 3 STUDY
    • NEOSTEM RANKED AS ONE OF THE FASTEST GROWING COMPANIES IN NEW YORK CITY
    • CESCA THERAPEUTICS ANNOUNCES AGREEMENT WITH NEW YORK UPSTATE CORD BLOOD BANK
    • OXFORD BIOMEDICA ACQUIRES WINDRUSH COURT OFFICE AND LABORATORY FACILITIES
    • ASTELLAS ANNOUNCES RESEARCH COLLABORATION WITH HARVARD MEDICAL SCHOOL INVESTIGATOR FOR TREATMENT OF RETINAL DEGENERATION
    • OXFORD BIOMEDICA ANNOUNCES NEW PROCESS DEVELOPMENT AND MANUFACTURING COLLABORATION WHICH INCLUDES LENTIVECTOR LICENCE AGREEMENT
    • BONE THERAPEUTICS EXTENDS ALLOB PHASE I/IIA TRIAL TO GERMANY
    • BRAINSTORM GETS FDA FAST-TRACK STATUS FOR ALS STEM CELL THERAPY
    • TC BIOPHARM AND SISTEMIC ANNOUNCE COLLABORATION TO DEVELOP AN INNOVATIVE RANGE OF CANCER-SPECIFIC THERANOSTIC PRODUCTS
    • HISTOGENICS AND INTREXON ANNOUNCE FORMATION OF EXCLUSIVE CHANNEL COLLABORATION FOR CARTILAGE REPAIR THERAPIES
    • RESEARCHERS DEVELOP NOVEL GENE/CELL THERAPY APPROACH FOR LUNG DISEASE
    • MESOBLAST PARTNER JCR PHARMACEUTICALS FILES FOR MARKETING APPROVAL OF THE FIRST ALLOGENEIC STEM CELL PRODUCT IN JAPAN
    • CESCA THERAPEUTICS ANNOUNCES APPROVAL OF ITS AXP(R) AUTOXPRESS(R) SYSTEM IN TAIWAN
    • HORIZON DISCOVERY GROUP PLC ACQUIRES SAGE LABS INC
    • BAXTER TO FORM NEW GLOBAL INNOVATION AND R&D CENTER NEAR BOSTON FOR ITS BIOPHARMACEUTICALS BUSINESS
    • ADVANCED CELL TECHNOLOGY ANNOUNCES FINAL PATIENT TREATED IN STARGARDT'S MACULAR DEGENERATION PHASE 1 TRIAL IN THE UNITED KINGDOM
    • FIBROCELL SCIENCE AND INTREXON ADVANCE GM-HDF-COL7 TOWARD CLINICAL DEVELOPMENT FOR THE TREATMENT OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
    • GENZYME COLLABORATES ON GENE THERAPY FOR RARE DISEASE THAT CAUSES CHILDHOOD BLINDNESS
    • STUDY DETERMINES MIMEDX ALLOGRAFT EFFECTIVELY RECRUITS CIRCULATING STEM AND PROGENITOR CELLS
    • BIOLIFE SOLUTIONS AND SAVSU TECHNOLOGIES ANNOUNCE EXCLUSIVE DISTRIBUTION AGREEMENT
    • UTSW RESEARCHERS WORKING TO REGENERATE HEART, NERVE CELLS
    • MAYO CLINIC CENTER FOR REGENERATIVE MEDICINE FORMS COLLABORATION WITH NATIONAL UNIVERSITY IRELAND GALWAY
    • ACCUREXA ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH UC SAN FRANCISCO
    • MEDPACE CONTINUES TO EXPAND THERAPEUTIC LEADERSHIP IN ONCOLOGY DRUG DEVELOPMENT
    • REGENERATIVE MEDICINE TO BE INSURED
    • MIMEDX SIGNS DISTRIBUTION AGREEMENT WITH ZIMMER
    • CANCER RESEARCH UK, CANCER RESEARCH TECHNOLOGY AND ASTERIAS BIOTHERAPEUTICS PARTNER TO TRIAL IMMUNOTHERAPY VACCINE FOR LUNG CANCER
    • MABVAX THERAPEUTICS ENTERS AGREEMENTS WITH MEMORIAL SLOAN KETTERING CANCER CENTER AND JUNO THERAPEUTICS FOR DEVELOPMENT OF ANTI-CANCER THERAPEUTICS
    • SANGAMO BIOSCIENCES ANNOUNCES TARGET DATE FOR FIRST IND FOR SANGAMO'S IN VIVO ZFN GENOME-EDITING PLATFORM FOR MONOGENIC DISEASES
    • STEM CELL AGENCY INVESTS $16 MILLION TO FIGHT DIABETES AND ANNOUNCES PLAN TO LAUNCH CIRM 2.0
    • HARVARD APPARATUS REGENERATIVE TECHNOLOGY OBTAINS ORPHAN DRUG DESIGNATION FROM U.S. FOOD AND DRUG ADMINISTRATION FOR HART-TRACHEA
    • SCIENTISTS FIND WAY TO EXPAND BLOOD STEM CELL PRODUCTION IN LAB
    • ABBVIE AND CALICO ANNOUNCE A NOVEL COLLABORATION TO ACCELERATE THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF NEW THERAPIES
    • ARTIFICIAL VIRUS PROMISES EFFECTIVE DRUG DELIVERY AND GENE THERAPY
    • CELLULAR BIOMEDICINE GROUP LAUNCHES CLINICAL RESEARCH STUDY FOR CARTILAGE DEFECT STEM CELL THERAPY
    • BONE THERAPEUTICS SUPPORTS PIONEERING RESEARCH BY BACKING PROJECTS VITAL TO REGENERATIVE MEDICINE RESEARCH
    • REGENEUS'S HIQCELL OBTAINS APPROVAL FROM AFL
    • BIOTIME TO COLLABORATE WITH THE UNIVERSITY OF WISCONSIN AND LOUVAIN UNIVERSITY IN TEST OF HYSTEM-BASED HYDROGEL FOR VOCAL FOLD SCARRING
    • PAVING THE WAY FOR GENE THERAPY IN HUNTINGTON'S DISEASE
    • ASTERIAS BIOTHERAPEUTICS RECEIVES U.S. FDA CLEARANCE TO INITIATE PHASE 1/2A CLINICAL TRIAL OF AST-OPC1 IN PATIENTS WITH CERVICAL COMPLETE SPINAL CORD INJURY
    • CESCA THERAPEUTICS ADVOCATES BENEFITS OF CELL THERAPY TO THE CENTERS FOR MEDICARE AND MEDICAID SERVICES
    • MESOBLAST UNVEILS PATH TO BRING ITS KEY PRODUCTS TO MARKET
    • REGENEUS ENTERS PARTNERSHIP WITH CRYOSITE FOR NEW STEM CELL PRODUCTS
    • BIOLIFE SOLUTIONS CRYOSTOR AND HYPOTHERMOSOL NOW EMBEDDED IN 130 REGENERATIVE MEDICINE CLINICAL TRIALS
    • VIACYTE, INC. ANNOUNCES SIGNING OF RIGHTS AGREEMENT WITH JANSSEN RESEARCH & DEVELOPMENT LLC.
    • CYTOMEDIX PARTNERS WITH NET HEALTH TO EXPAND CED DATA COLLECTION CAPABILITIES TO APPROXIMATELY 400 ADDITIONAL WOUND CARE CENTERS
    • NOVARTIS TO INVEST IN ISRAEL'S GAMIDA CELL, COULD BUY OUT COMPANY
    • BARDA EXECUTES CONTRACT OPTION WITH CYTORI FOR CONTINUED DEVELOPMENT OF THERMAL BURN INJURY COUNTER MEASURE
    • VIACYTE, INC. ANNOUNCES FDA ACCEPTANCE OF IND TO COMMENCE CLINICAL TRIAL OF VC-01 CANDIDATE CELL REPLACEMENT THERAPY FOR TYPE 1 DIABETES
    • FDA CLEARS MAYO CLINIC FOR MANUFACTURE OF NUROWN AND PARTICIPATION IN BRAINSTORM'S PHASE 2 ALS TRIAL
    • ENGINEERING NEW BONE GROWTH
    • THE ALLIANCE FOR REGENERATIVE MEDICINE AND THE ALLIANCE FOR ADVANCED THERAPIES MERGE
    • TISSUE DEVELOPMENT 'ROADMAP' CREATED TO GUIDE STEM CELL MEDICINE
    • ORGANOVO TO OFFER PRECLINICAL DRUG TESTS BASED ON 3-D LIVER TISSUE
    • CEDARS-SINAI HEART INSTITUTE OPENS FIRST-OF-ITS-KIND RESEARCH STEM CELL CLINIC FOR CARDIAC PATIENTS
    • 3-D BIOENGINEERED BRAIN TISSUE GROWN IN LAB
    • STEM CELL THERAPY: FDA REGULATORY SCIENCE AIMS TO FACILITATE DEVELOPMENT OF SAFE AND EFFECTIVE REGENERATIVE MEDICINE PRODUCTS
    • UNIQURE ACQUIRES CARDIOLOGY GENE THERAPY COMPANY INOCARD
    • HUMAN LONGEVITY, INC. AND CELGENE CELLULAR THERAPEUTICS SIGN LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE PLACENTAL STEM CELL POPULATION, PSC-100 FOR MULTIPLE THERAPEUTIC APPLICATIONS
    • VIVEX BIOMEDICAL AND AKRON BIOTECH: COLLABORATIVE VENTURE IN REGENERATIVE MEDICINE
    • JAPAN'S REPROCELL ANNOUNCES ACQUISITION OF TWO STEM CELL COMPANIES
    • CHIESI AND UNIQURE PROVIDE UPDATE ON GLYBERA LAUNCH
    • BIOLIFE SOLUTIONS CRYOSTOR DEMONSTRATES SUPERIOR CELL PRESERVATION IN MULTICENTER BIOBANKING STUDY
    • CELLULAR BIOMEDICINE GROUP ANNOUNCES ACQUISITION OF IMMUNE CELL THERAPY TECHNOLOGY AND U.S. PATENT
    • BIOLIFE SOLUTIONS CRYOSTOR DEMONSTRATES SUPERIOR CELL PRESERVATION IN MULTICENTER BIOBANKING STUDY
    • LIGHT-INDUCED NANOCARRIERS SWITCH ON IMPROVED GENE THERAPY
    • ORTHOCELL DELIVERS EXCELLENT RESULTS IN TENNIS ELBOW TRIAL
    • MESOBLAST MPCS TRIAL TO TEST FOR END-STAGE HEART FAILURE
    • BIOTIME, INC. SUBSIDIARY ONCOCYTE CORPORATION EXPANDS CLINICAL DEVELOPMENT OF BLADDER CANCER DIAGNOSTIC BY INITIATING A LARGE MULTI-SITE CLINICAL TRIAL
    • CARNEGIE MELLON CHEMISTS CREATE NANOFIBERS USING UNPRECEDENTED NEW METHOD
    • CELLECTIS SELLS ITS SWEDISH SUBSIDIARY, CELLECTIS AB, TO THE JAPANESE COMPANY TAKARA BIO INC.
    • WYSS INSTITUTE LAUNCHES ORGANS-ON-CHIPS-FOCUSED STARTUP
    • STEM CELL ADVANCE MAY INCREASE EFFICIENCY OF TISSUE REGENERATION
    • LION BIOTECHNOLOGIES ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH MOFFITT CANCER CENTER
    • WHITEHEAD INSTITUTE RESEARCHERS CREATE "NAÏVE" PLURIPOTENT HUMAN EMBRYONIC STEM CELLS
    • 3-D PRINTED TISSUES ADVANCE STEM CELL RESEARCH
    • ZIOPHARM ANNOUNCES EXPANSION OF GROUND-BREAKING SYNTHETIC IMMUNO-ONCOLOGY PROGRAMS WITH INTREXON AND CLINICAL PROGRAM UPDATE
    • LILLY AND IMMUNOCORE ENTER IMMUNOTHERAPY AGREEMENT TO CO-DISCOVER AND CO-DEVELOP NOVEL CANCER THERAPIES
    • TRANSPLANTING GENE INTO INJURED HEARTS CREATES BIOLOGICAL PACEMAKERS
    • STEM CELL THERAPY IN CARDIOVASCULAR DISEASE: PAST OBSTACLES AND PROMISING NEW DIRECTIONS
    • MICROBIOLOGICS LICENSES BIOMATRICA TECHNOLOGY FOR MOLECULAR CONTROLS
    • REGENEUS SECURES EXCLUSIVE WORLDWIDE RIGHTS FOR NEW THERAPEUTIC HUMAN CANCER VACCINE
    • UNIVERSITY OF PENNSYLVANIA'S PERSONALIZED CELLULAR THERAPY FOR LEUKEMIA RECEIVES FDA'S BREAKTHROUGH THERAPY DESIGNATION
    • RESEARCHERS REGROW HUMAN CORNEAS: FIRST KNOWN TISSUE GROWN FROM A HUMAN STEM CELL
    • STEM CELLS: HOPE ON THE LINE
    • IMPROVING STEM CELLS' REGENERATIVE POTENTIAL
    • ETHICS OF BIOENGINEERING ORGANS AND TISSUES
    • MESOBLAST MPCS SHOW ENCOURAGING RESULTS IN TREATING HEART FAILURE
    • BLUEBIRD BIO ACQUIRES PRECISION GENOME ENGINEERING, A PRIVATELY HELD GENE-EDITING COMPANY
    • REGENEUS ENTERS INTO US MARKETING TRIAL AGREEMENT FOR NOVEL CANINE CANCER VACCINE
    • AGTC AND SAFC CREATE STRATEGIC PARTNERSHIP TO PROVIDE GENE THERAPY MANUFACTURING SERVICES
    • DIMENSION THERAPEUTICS AND BAYER HEALTHCARE ENTER COLLABORATION TO DEVELOP NOVEL GENE THERAPY FOR HEMOPHILIA A
    • UT SOUTHWESTERN RESEARCHERS DISCOVER BIOMARKER FOR MESENCHYMAL STROMAL CELL FUNCTION IN HUMAN BODY
    • PFIZER AND CELLECTIS ENTER INTO GLOBAL STRATEGIC CANCER IMMUNOTHERAPY COLLABORATION
    • FIBROCELL SCIENCE ANNOUNCES EXCLUSIVE TECHNOLOGY LICENSE AGREEMENTS WITH UCLA TO ADVANCE THE DEVELOPMENT OF PERSONALIZED CELL THERAPIES
    • AASTROM ANNOUNCES STRATEGIC PLAN FOR RECENTLY ACQUIRED CELL THERAPY AND REGENERATIVE MEDICINE BUSINESS
    • CCRM AND STEM CELLS AUSTRALIA AGREE TO COLLABORATE IN THE GLOBAL TRANSLATION OF STEM CELL RESEARCH
    • CARDIO3 BIOSCIENCES TEAMS UP WITH MEDISUN INTERNATIONAL TO CREATE CARDIO3 BIOSCIENCES ASIA HOLDINGS LTD, A JOINT VENTURE AIMED AT CONDUCTING PIVOTAL CLINICAL PROGRAMS IN GREATER CHINA
    • TXCELL GRANTED CERTIFICATE OF GMP COMPLIANCE FROM ANSM FOR CELL THERAPY MANUFACTURING FACILITY
    • UCLB SIGNS EXCLUSIVE LICENCING AGREEMENT WITH COLLAGEN SOLUTIONS FOR NEXT GENERATION COLLAGEN PRODUCTS
    • CELLECTIS ENTERS INTO AN AGREEMENT WITH CELLFORCURE FOR THE CGMP MANUFACTURING OF ALLOGENEIC CART CELLS
    • ADAPTIMMUNE ENTERS STRATEGIC CANCER IMMUNOTHERAPY COLLABORATION WITH GLAXOSMITHKLINE TO DEVELOP AND COMMERCIALISE NOVEL CELL-BASED THERAPIES
    • AASTROM COMPLETES ACQUISITION OF SANOFI'S CELL THERAPY AND REGENERATIVE MEDICINE BUSINESS
    • PHARMACELL TO FINALIZE PURCHASE OF CELL THERAPY PRODUCTION FACILITY
    • MESOBLAST'S MPCS ENHANCE OUTCOMES IN TYPE 2 DIABETES
    • ORTHO-ATI DELIVERS PROMISING RESULTS IN TREATING HIP TENDON PAIN
    • STEM CELL AGENCY INVESTS $32 MILLION TOWARD THERAPIES FOR SPINAL CORD INJURY AND HIV/AIDS
    • SANGAMO BIOSCIENCES ANNOUNCES PUBLICATION OF PRECLINICAL DATA DEMONSTRATING GENE CORRECTION IN SCID-X1 HUMAN HEMATOPOIETIC STEM CELLS
    • DEVICE PRODUCES PACKAGED BATCHES OF STEM CELLS FOR REGENERATIVE MEDICINE
    • BIORESTORATIVE THERAPIES SIGNS RESEARCH AGREEMENT WITH PFIZER INC.
    • ROSLIN CELLS ANNOUNCES NEW CELL THERAPY MANUFACTURING CONTRACT WITH PFIZER INC.
    • PLURISTEM RECEIVES CLEARANCE FROM SOUTH KOREA TO USE PLX CELLS MANUFACTURED AT ITS NEW FACILITY IN ITS ADVANCES STUDIES
    • NEOSTEM ANNOUNCES LICENSING AGREEMENT AND PLANS TO BEGIN PHASE 2 HEPATOCELLULAR CARCINOMA TRIAL IN CHINA
    • PATIENT STEM CELLS USED TO MAKE 'HEART DISEASE-ON-A-CHIP'
    • NOVEL METHOD GROWS CORD BLOOD CELLS FOR MEDICAL APPLICATIONS
    • REGENERON AND AVALANCHE BIOTECHNOLOGIES ANNOUNCE COLLABORATION TO DEVELOP NEXT-GENERATION GENE THERAPY PRODUCTS IN OPHTHALMOLOGY
    • MESOBLAST SEEKS FDA FAST-TRACK FOR GVHD TREATMENT
    • NEW HOPE IN REGENERATIVE MEDICINE
    • REGENX BIOSCIENCES ENTERS INTO LICENSE AGREEMENT WITH AAVLIFE FOR DEVELOPMENT OF TREATMENTS FOR FRIEDREICH'S ATAXIA USING NAV® VECTORS
    • AVITA MEDICAL LAUNCHES ENHANCED RECELL SPRAY-ON SKIN VERSION
    • BRISTOL-MYERS SQUIBB ACQUIRES IPIERIAN, INC.
    • MD ANDERSON ANNOUNCES IMMUNOTHERAPY COLLABORATION WITH GSK
    • NEOSTEM ANNOUNCES DEFINITIVE AGREEMENT TO ACQUIRE CALIFORNIA STEM CELL, INC
    • AKRON BIOTECH AWARDED SBIR GRANT FOR DEVELOPMENT OF NOVEL METHOD TO ISOLATE ADIPOSE DERIVED STEM CELLS
    • MD ANDERSON ANNOUNCES IMMUNOTHERAPY COLLABORATION WITH GSK
    • RECELL CONTAINING AMBIENT-STORED ENZYME LAUNCHED IN UNITED KINGDOM AND EUROPE
    • BAXTER TO ACQUIRE CHATHAM THERAPEUTICS
    • REGENX BIOSCIENCES AND AVEXIS ENTER INTO EXCLUSIVE AGREEMENT FOR DEVELOPMENT OF TREATMENTS FOR SMA
    • ASTELLAS: ESTABLISHMENT OF REGENERATIVE MEDICINE UNIT
    • COMPANIES COLLABORATE TO ADVANCE DOMINANT RP GENE THERAPY
    • BIOHEART ANNOUNCES CLINICAL STUDY FOR DEGENERATIVE DISC DISEASE
    • GENE THERAPY'S BIG COMEBACK
    • SURVEY OF PHARMA AND LARGE-CAP BIOTECH SHOWS SIGNIFICANT INVESTMENT IN REGENERATIVE MEDICINE
    • SPARK THERAPEUTICS AND GENABLE TECHNOLOGIES ANNOUNCE COLLABORATION TO ADVANCE A GENE THERAPY TREATMENT FOR A RARE FORM OF RETINITIS PIGMENTOSA
    • BRAINSTORM AND MASSACHUSETTS GENERAL HOSPITAL SIGN DEFINITIVE AGREEMENT FOR ALS CLINICAL TRIAL
    • BRAINSTORM GRANTED KEY US PATENT FOR ITS AUTOLOGOUS STEM CELL TECHNOLOGY
    • MEDINET BUILDS STRATEGIC PARTNERSHIP WITH TC BIOPHARM FOR THE DEVELOPMENT AND SALES OF A IMMUNO-CELL MEDICINAL PRODUCT IN EUROPE
    • TAKEDA, UCL PARTNER IN $250K STUDY OF TREATING MD WITH IPS CELLS
    • HISTOGEN AESTHETICS ACQUIRES CELLCEUTICALS BIOMEDICAL SKIN TREATMENTS
    • SCIENTIST URGES WITHDRAWAL OF HIS OWN 'BREAKTHROUGH' STEM CELL RESEARCH
    • CARDIAC STEM CELL THERAPY AND THE PROMISE OF HEART REGENERATION
    • AMERICA MAKES FUNDING CONTRACT ENABLES PITT RESEARCHERS TO EXPLORE 3-D-PRINTED BONE AND TISSUE SCAFFOLDS
    • HEALIOS AND DAINIPPON SUMITOMO PHARMA ESTABLISH A JOINT VENTURE COMPANY FOR REGENERATIVE MEDICINE AND CELL THERAPY BUSINESS
    • NEOSTEM AND MASS. EYE AND EAR/SCHEPENS EYE RESEARCH INSTITUTE ANNOUNCE SECOND RESEARCH COLLABORATION EXPLORING NEOSTEM'S VSEL™ TECHNOLOGY FOR RETINAL REPAIR
    • DENDREON ANNOUNCES PLANS TO MAKE PROVENGE ® COMMERCIALLY AVAILABLE IN EUROPE
    • ADMEDUS OBTAINS FDA APPROVAL FOR CARDIOCEL
    • CINVEN INVESTS IN MEDPACE, CITING STRONG GROWTH DRIVERS IN THE CRO MARKET
    • REGENX BIOSCIENCES AND ESTEVE ENTER INTO LICENSE AGREEMENT FOR RARE LYSOSOMAL STORAGE DISORDER
    • PLASTICELL SIGNS DEAL WITH JCR PHARMACEUTICALS TO USE COMBICULT® STEM CELL TECHNOLOGY IN JAPAN
    • CELL THERAPY CATAPULT & UNIVERSITY OF LEEDS TO COLLABORATE ON ACELLULAR SCAFFOLDS
    • SCIENTISTS DEVELOP STEM CELL BASED METHOD FOR RESTORING STRENGTH TO DAMAGED SKELETAL MUSCLES IN ELDERLY
    • PARCELL LABORATORIES PARTNERS WITH THE UNIVERSITY OF PITTSBURGH MEDICAL CENTER TO STUDY EFFECTIVE STEM CELL-BASED WRINKLE TREATMENTS
    • PRIMA BIOMED AND NEOPHARM GROUP EXECUTE FINAL AGREEMENT FOR CVAC LICENSE PRIMA BIOMED UND DIE NEOPHARM GROUP SCHLIEẞEN FINALE VEREINBARUNG ÜBER CVAC-LIZENZ
    • KEY EUROPEAN PATENT GRANTED FOR USE OF MESOBLAST'S MESENCHYMAL PRECURSOR CELLS IN CARDIAC AND VASCULAR CONDITIONS
    • PLURISTEM RECEIVES KEY 3D CELL EXPANSION PATENT IN AUSTRALIA
    • GENEA BIOCELLS BECOMES THE WORLD'S LARGEST PROVIDER OF HUMAN EMBRYONIC STEM CELLS
    • CYNATA THERAPEUTICS SIGNS STEM CELL AGREEMENT WITH WAISMAN BIOMANUFACTURING
    • UNIQURE ANNOUNCES CLOSING OF INITIAL PUBLIC OFFERING
    • CALIFORNIA STEM CELL PARTNERS ON CIRM GRANT TO DEVELOP TRANSPLANTABLE 3D RETINAS
    • RIKEN, KYOTO UNIVERSITY TO PARTNER IN STAP CELL APPLICATIONS
    • BRAINSTORM RECEIVES US NOTICE OF ALLOWANCE FOR ITS KEY STEM CELL TECHNOLOGY PATENT
    • MESOBLAST'S MPCS SHOWN TO ALLEVIATE BACK PAIN IN PHASE II TRIAL
    • REGENEUS TO COLLABORATE WITH LONZA FOR US CRYOSHOT TRIAL
    • BRAINSTORM SIGNS DEFINITIVE AGREEMENT WITH MAYO CLINIC FOR ALS CLINICAL TRIAL AND NUROWN MANUFACTURING
    • KIADIS PHARMA INITIATES COLLABORATION FOR PERSONALIZED IMMUNOTHERAPIES USING ATIR™ WITH TECHNISCHE UNIVERSITÄT MÜNCHEN WITHIN MUNICH BIOTECH CLUSTER
    • MEDIGENE ACQUIRES TRIANTA IMMUNOTHERAPIES
    • TIGENIX TO SELL DUTCH MANUFACTURING FACILITY TO PHARMACELL
    • PHARMACELL TO PURCHASE CELL THERAPY PRODUCTION FACILITY FROM TIGENIX
    • NEWS RELEASE: REGENEUS PARTNERS WITH LONZA FOR MANUFACTURING CRYOSHOT CANINE CELL THERAPY PRODUCT FOR US FDA TRIAL
    • ORGANOGENESIS INC. ANNOUNCES ACQUISITION OF DERMAGRAFT® FROM SHIRE
    • DERMA SCIENCES ENTERS THE SKIN SUBSTITUTE MARKET WITH LICENSING AGREEMENT FOR INNOVATIVE AMNIOTIC MEMBRANE WOUND CARE PRODUCTS
    • ORGANOVO ANNOUNCES COLLABORATION WITH NATIONAL INSTITUTES OF HEALTH
    • ATHERSYS ANNOUNCES NEW PATENTS IN JAPAN FOR STEM CELL AND REGENERATIVE MEDICINE TECHNOLOGY
    • BIOGEN IDEC AND SANGAMO BIOSCIENCES ANNOUNCE GLOBAL COLLABORATION TO DEVELOP TREATMENTS FOR HEMOGLOBINOPATHIES
    • CELLULAR DYNAMICS SIGNS AGREEMENT WITH NESTLE INSTITUTE OF HEALTH SCIENCES TO SUPPLY ICELL(R) AND MYCELL(R) PRODUCTS FOR NUTRITIONAL RESEARCH
    • IMMUNOCORE AND MEDIMMUNE ENTER IMMUNOTHERAPY AGREEMENT TO DEVELOP NOVEL CANCER THERAPIES
    • THERMOGENESIS SIGNS DIRECT SUPPLY AGREEMENT WITH CORD BLOOD REGISTRY
    • PLURISTEM RECEIVES KEY PLACENTAL CELL THERAPY PATENT IN AUSTRALIA
    • BAYLOR COLLEGE OF MEDICINE, CHI ST. LUKE'S HEALTH, TEXAS HEART INSTITUTE COLLABORATION: EXECUTIVE BIOGRAPHIES
    • CAPRICOR THERAPEUTICS AND JANSSEN BIOTECH, INC. ENTER INTO COLLABORATION AGREEMENT AND EXCLUSIVE LICENSE OPTION
    • THERMO FISHER SCIENTIFIC REACHES AGREEMENT TO SELL ITS CELL CULTURE, GENE MODULATION AND MAGNETIC BEADS BUSINESSES TO GE HEALTHCARE
    • PALL CORP. SIGNS AGREEMENT TO ACQUIRE ATMI'S LIFESCIENCES BUSINESS
    • INTREXON TO ACQUIRE MEDISTEM TO GENERATE MULTIPOTENT CELLS
    • AMERICA STEM CELL, INC. CHANGES ITS NAME TO TARGAZYME, INC.
    • NOVARTIS NEEDS SPECIAL DELIVERY FOR POTENT CELL THERAPY
    • REGENERATIVE MEDICINE: MAYO CLINIC AND COLLABORATORS DEVELOP NEW TOOL FOR TRANSPLANTING STEM CELLS
    • REGENX AND LYSOGENE ENTER INTO LICENSE AGREEMENT FOR TREATMENT OF MPS IIIA USING RAAVRH10 VECTORS
    • JAIN FOUNDATION SIGNS AGREEMENT WITH CELLULAR DYNAMICS TO CREATE IPSC LINES FROM PATIENTS WITH MUSCULAR DYSTROPHIES
    • NYSCF AND PERSONALGENOMES.ORG IN GROUNDBREAKING COLLABORATION COMBINE GENOMIC SEQUENCING AND STEM CELL TECHNOLOGY TO UNDERSTAND HUMAN DISEASE
    • SINGAPORE SCIENTISTS MAKE BREAKTHROUGH IN REGENERATIVE MEDICINE
    • ASTRAZENECA, LIEBER INSTITUTE JOIN TO DEVELOP NEUROSCIENCE THERAPEUTICS
    • TXCELL OBTAINS MANUFACTURING ACCREDITATION STATUS FOR ITS FRENCH CELL THERAPY MANUFACTURING FACILITY
    • LIVING CELL OBTAINS APPROVAL TO CONTINUE PARKINSON'S TRIAL
    • AUSSIE STEM CELL FIRMS SWITCH TO JAPANESE FAST LANES
    • MESOBLAST'S MPCS ENHANCE CARDIAC FUNCTION
    • MESOBLAST'S PARTNER ALLOWED TO CONDUCT PHASE III HEART TRIAL
    • SCIENTISTS CREATE ARTIFICIAL SKIN FROM STEM CELLS OF UMBILICAL CORD
    • MOLMED ENTERS AN AGREEMENT WITH GSK FOR THE MANUFACTURE OF THE EXPERIMENTAL GENE THERAPY FOR COMPASSIONATE USE FOR ADA-SCID
    • Q THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION FROM U.S. FOOD & DRUG ADMINISTRATION FOR Q-CELLS® FOR TREATMENT OF ALS
    • AMERICAN CRYOSTEM AND PROTEIN GENOMICS FORM AUTOGENESIS CORPORATION TO SUPPORT DEVELOPMENT OF UNIQUE STEM CELL-BASED WOUND PRODUCTS
    • TERUMO BCT RELEASES SOFTWARE 2 FOR QUANTUM CELL EXPANSION SYSTEM
    • GE HEALTHCARE LIFE SCIENCES LAUNCHES XURI™ TECHNOLOGY FAMILY FOR CELL THERAPY MANUFACTURING
    • NEOSTEM SUBSIDIARY PROGENITOR CELL THERAPY ANNOUNCES CELL THERAPY MANUFACTURING COLLABORATION WITH ATMI
    • MERCK SERONO, KADIMASTEM COLLABORATE ON CELL-BASED DRUG SCREENING
    • STEM CELLS FOR REGENEUS
    • FIDELITY BIOSCIENCES AND REGENX BIOSCIENCES LAUNCH DIMENSION THERAPEUTICS TO DEVELOP AND COMMERCIALIZE NOVEL AAV GENE THERAPY PRODUCTS
    • STEMCELLS, INC. ACQUIRES SEMINAL NEURAL STEM CELL PATENT PORTFOLIO
    • MESOBLAST UPDATES MARKET ON REGISTRATION PLANS FOR GVHD CELL PRODUCT IN JAPAN
    • MESOBLAST ACQUIRES OSIRIS' CULTURE EXPANDED STEM CELL THERAPEUTIC BUSINESS
    • TAP BIOSYSTEMS GROUP PLC ANNOUNCES ACQUISITION OFFER BY SARTORIUS STEDIM BIOTECH
    • ASTERIAS BIOTHERAPEUTICS, INC., A SUBSIDIARY OF BIOTIME, INC., ACQUIRES GERON'S EMBRYONIC STEM CELL ASSETS
    • MESOBLAST TO ACQUIRE STEM CELL BUSINESS FROM OSIRIS
    • FIRST PARKINSON'S PATIENT IMPLANTED WITH LCT'S NTCELL
    • EFFICACY OF ALLIED'S CARDIOCEL PROVEN IN A LONG-TERM TEST.
    • BIOHEART ANNOUNCES AGREEMENT WITH INVITRX TO LICENSE ADIPOSE DERIVED STEM CELLS
    • BIOTIME SIGNS EXCLUSIVE AGREEMENT WITH JADE THERAPEUTICS FOR OPHTHALMIC DRUG DELIVERY APPLICATIONS OF HYSTEM® TECHNOLOGY
    • REINNERVATE LTD AND ROSLIN CELLAB TO PARTNER AROUND 3D STEM CELL PRINTING PRODUCTS AND TECHNOLOGIES
    • HARVARD'S WYSS INSTITUTE AND CHARITÉ, ONE OF EUROPE'S LARGEST UNIVERSITY HOSPITALS, ANNOUNCE PARTNERSHIP
    • EVOTEC AND HARVARD STEM CELL INSTITUTE FORM CUREMN COLLABORATION TO ADVANCE ALS RESEARCH
    • CELL THERAPY CATAPULT & ROSLIN CELLS TO CREATE CLINICAL GRADE STEM CELLS TO ACCELERATE RESEARCH INTO NEW TREATMENTS
    • SERNOVA AND MEDICYTE TO COLLABORATE ON CELL-BASED THERAPY TO TREAT HAEMOPHILIA
    • NOVARTIS ANNOUNCES AN EXCLUSIVE GLOBAL LICENSING AND RESEARCH COLLABORATION WITH REGENEREX, LEVERAGING A NOVEL CELL PLATFORM TO BROADEN PRESENCE IN THE CELL THERAPY SPACE
    • LLIED HEALTHCARE SECURES IMPORTANT CE MARK FOR CARDIOCEL
    • AVITA ENLISTS FIRST THREE PATIENTS FOR RECELL SPRAY ON SKIN TRIAL
    • AVITA MEDICAL ANNOUNCES COMPLETION OF ENROLLMENT IN RECELL® TRIAL FOR VITILIGO
    • SANGAMO BIOSCIENCES TO ACQUIRE CEREGENE
    • FDA APPROVES MSC-NP THERAPY AS INVESTIGATIONAL NEW DRUG IN MS CLINICAL TRIAL: A RESEARCH MILESTONE
    • VITAL THERAPIES, INC. RECEIVES ORPHAN DESIGNATION IN EUROPE
    • DOORS OPEN FOR AUSTRALIAN BIOTECH COMPANIES IN SWITZERLAND
    • REGENX BIOSCIENCES AND AUDENTES THERAPEUTICS ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR DEVELOPMENT OF TREATMENTS FOR SERIOUS, RARE MUSCLE DISEASES USING NAVTM VECTORS
    • STEMCELLS, INC. LAUNCHES ALZHEIMER'S DISEASE PROGRAM SUPPORTED BY CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE
    • BRAINSTORM'S NUROWN CELL THERAPY RECEIVES ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR ALS
    • BIOTECH FIRM'S STEM-CELL DEAL COULD REAP REWARDS IN CHINA
    • TRANSATLANTIC PARTNERSHIP TO TACKLE NEURODEGENERATIVE DISEASE
    • THERMOGENESIS AND TOTIPOTENTRX ANNOUNCE DEFINITIVE MERGER AGREEMENT
    • NEOSTEM ADVANCES AUTOIMMUNE PLATFORM THROUGH UCSF COLLABORATION
    • SERNOVA RECEIVES PATENT ALLOWANCE FOR THERAPEUTIC IMMUNE PRIVILEGED CELL TECHNOLOGIES
    • CAPRICOR AND NILE THERAPEUTICS ANNOUNCE MERGER AGREEMENT
    • PLURISTEM'S SOUTH KOREAN PARTNER FILES IND WITH KOREAN FDA FOR PLX CELLS
    • MESOBLAST WINS JAPANESE PATENT FOR STEM CELL PLATFORM
    • LIFE TECHNOLOGIES EXPANDS RANGE OF STEM CELL REPROGRAMMING SOLUTIONS
    • EMD MILLIPORE LAUNCHES PLURISTEM™ HUMAN ES/IPS MEDIUM FOR THE EXPANSION OF HUMAN EMBRYONIC AND INDUCED PLURIPOTENT STEM CELLS
    • CTI CLINICAL TRIAL AND CONSULTING SERVICES ANNOUNCES ACQUISITION OF S2 STATISTICAL SOLUTIONS
    • OUR LADY OF LOURDES MEDICAL CENTER & THE HEART HOUSE PARTICIPATING IN RESEARCH STUDY USING ADULT STEM CELLS FOR CHRONIC CARDIAC CONDITION
    • STEM CELLS REACH STANDARD FOR USE IN DRUG DEVELOPMENT
    • MESOBLAST'S PRECLINICAL TRIAL RESULTS OF INTRACORONARY CELL THERAPY PUBLISHED IN CIRCULATION RESEARCH
    • AMERICAN CRYOSTEM TO COLLABORATE WITH RUTGERS UNIVERSITY ON ADIPOSE-DERIVED STEM CELL RESEARCH
    • A*STAR'S GENOME INSTITUTE OF SINGAPORE PARTNERS OXFORD BIODYNAMICS TO DISCOVER AND MONITOR CELLS FOR PATHOLOGIES OR ABNORMALITIES
    • PLURISTEM DEVELOPS PLX-RAD CELLS FOR USE IN HEMATOLOGY
    • VISTAGEN THERAPEUTICS AND DUKE UNIVERSITY PUBLISH RESULTS ON PRODUCTION OF FUNCTIONAL 3D HUMAN HEART TISSUE
    • MILTENYI BIOTEC ACQUIRES OWL BIOMEDICAL, INC.
    • AMERICAN CRYOSTEM MARKS MAJOR GLOBAL EXPANSION MILESTONE: RECEIVES FIRST INTERNATIONAL SHIPMENT OF ADIPOSE TISSUE FOR PROCESSING AND CRYO-STORAGE FROM HONG KONG
    • TIGENIX REPORTS POSITIVE PHASE IIA STUDY RESULTS IN REFRACTORY RHEUMATOID ARTHRITIS WITH ALLOGENEIC STEM CELL PRODUCT CX611
    • BIOTIME ENTERS INTO WORLDWIDE LICENSE AGREEMENT WITH UCLA TO DEVELOP THERAPY FOR THE TREATMENT OF STROKE
    • STEM CELL THERAPEUTICS LICENSES EXCLUSIVE RIGHTS TO CLINICAL CANCER STEM CELL PROGRAM
    • NEURALSTEM RECEIVES FDA APPROVAL TO COMMENCE PHASE II STEM CELL TRIAL IN AMYTROPHIC LATERAL SCLEROSIS
    • LEADING THE WAY IN REGENERATIVE MEDICINE
    • THERMO FISHER SCIENTIFIC TO ACQUIRE LIFE TECHNOLOGIES CORPORATION
    • VISTAGEN ANNOUNCES $36 MILLION STRATEGIC FINANCING AGREEMENT
    • BRAINSTORM PARTNERS WITH DANA-FARBER FOR NUROWN™ PRODUCTION IN PHASE II ALS CLINICAL TRIAL
    • MARYLAND INVESTS $500,000 IN GAITHERSBURG MEDICINE COMPANY
    • BIOHEART COMPLETES FDA REGISTRATION FOR TISSUE BANK ESTABLISHMENT
    • ELASTIC PATCH SUPPORTS CARDIAC CELL GROWTH
    • RENEURON AND CELL THERAPY CATAPULT IN LANDMARK COLLABORATION ON NEW CELL MANUFACTURING TECHNOLOGIES - FIRST UK CORPORATE DEAL FOR CT CATAPULT TO FOCUS ON RENEURON'S LEAD CELL THERAPY CANDIDATE
    • BLUEBIRD BIO ANNOUNCES GLOBAL STRATEGIC COLLABORATION WITH CELGENE TO ADVANCE GENE THERAPY IN ONCOLOGY
    • CRYO-CELL INTERNATIONAL AFFILIATE EARNS PATENT FOR PROCESSING UMBILICAL CORD BLOOD FOR THERAPEUTIC USE IN TREATING NEURODEGENERATIVE DISEASES AND SPINAL CORD AND BRAIN INJURIES
    • SISTEMIC AND PCT INITIATE STUDY ON NOVEL STEM CELL CHARACTERIZATION TECHNOLOGY
    • STEM CELL COMPANY ATHERSYS EXPECTS MORE R&D SPENDING, POTENTIAL PARTNERSHIPS IN 2013
    • HISTOGEN CREATES PUR BIOLOGICS, A JOINT VENTURE DEVELOPING NEXT-GENERATION, BIOLOGIC SOLUTIONS IN ORTHOPEDIC APPLICATIONS
    • U OF M RESEARCHERS UTILIZE GENETICALLY CORRECTED STEM CELLS TO SPARK MUSCLE REGENERATION
    • ROCHE AND BIOLAMINA START COLLABORATION TO DEVELOP NOVEL CELL CULTURE SYSTEMS
    • LIFE TECHNOLOGIES SIGNS LICENSE AND COLLABORATIVE STEM CELL RESEARCH AGREEMENT WITH HARVARD UNIVERSITY
    • VISTAGEN THERAPEUTICS ENTERS STRATEGIC COLLABORATION WITH CELSIS TO FURTHER ADVANCE LIVERSAFE 3D™
    • RIKEN TO APPLY FOR APPROVAL TO CONDUCT IPS CLINICAL RESEARCH
    • SERNOVA AND CENTRE FOR COMMERCIALIZATION OF REGENERATIVE MEDICINE PARTNER TO TREAT CHRONIC DISEASES
    • MODELING ALZHEIMER'S DISEASE USING IPSCS REVEALS STRESS PHENOTYPES ASSOCIATED WITH INTRACELLULAR AΒ AND DIFFERENTIAL DRUG RESPONSIVENESS
    • AN OPEN LABEL DOSE ESCALATION STUDY TO EVALUATE THE SAFETY OF ADMINISTRATION OF NON-VIRAL SDF-1 PLASMID TO TREAT SYMPTOMATIC ISCHEMIC HEART FAILURE
    • ORGANOVO PARTNERS WITH ZENBIO TO CREATE 3D TISSUE MODELS
    • ALLIED RECEIVES ISO CERTIFICATION FOR CARDIOCEL
    • MESOBLAST UP FOLLOWING PATENTS IN US AND CHINA
    • ALLIED FINDS CARDIOCEL BETTER AT SEEDING STEM CELLS
    • CYNATA'S STEM CELLS COULD POTENTIALLY TREAT CRITICAL LIMB ISCHEMIA
    • ALLIED HEALTHCARE RESEARCHES NEW TISSUE ENGINEERING APPLICATIONS
    • ORGANOVO AND OHSU KNIGHT CANCER INSTITUTE ANNOUNCE COLLABORATION IN CANCER RESEARCH
    • MONITORING AND ROBUST INDUCTION OF NEPHROGENIC INTERMEDIATE MESODERM FROM HUMAN PLURIPOTENT STEM CELLS
    • CELLULAR DYNAMICS ANNOUNCES THE PRODUCTION OF HUMAN IPSC LINES UNDER CGMP CONDITIONS
    • NEOSTEM'S SUBSIDIARY, PROGENITOR CELL THERAPY, ENTERS INTO A CELL THERAPY MANUFACTURING SERVICES AGREEMENT WITH ADAPTIMMUNE
    • NEW COLLABORATION BETWEEN CCRM AND NIKON TO REAP BENEFITS OUTSIDE THE LAB
    • SANBIO ANNOUNCES ENROLLMENT OF THE SECOND COHORT OF PATIENTS IN ITS CLINICAL TRIAL OF STEM CELL THERAPY FOR CHRONIC STROKE
    • NEURALSTEM RECEIVES FDA APPROVAL TO COMMENCE SPINAL CORD INJURY TRIAL
    • ALLIED HEALTHCARE EXPLORES NEW TISSUE ENGINEERING APPLICATIONS
    • TEXAS HEART INSTITUTE SELECTED TO STORE CELLS USED IN NATIONWIDE RESEARCH
    • ATHERSYS ANNOUNCES NEW PATENTS IN JAPAN FOR STEM CELL AND REGENERATIVE MEDICINE TECHNOLOGY
    • BRAINSTORM ACHIEVES IMPORTANT NEW DEVELOPMENT FOR COMMERCIALIZATION OF NUROWN
    • XTHERMO FISHER SCIENTIFIC EXPANDS CRYOPRESERVATION REAGENTS FOR CELL CULTURE
    • CANADIAN FIRM AIMS TO TREAT DIABETES NATURALLY WITH A CELL THERAPY/DEVICE COMBINATION
    • INDUSTRY LEADERS PREDICT A GREAT YEAR FOR REGENERATIVE MEDICINE
    • BRAINSTORM RECEIVES NOTICE OF ALLOWANCE TO GRANT EUROPEAN PATENT COVERING ITS STEM CELLS FOR THE TREATMENT OF CNS DISEASES
    • ADVANCED CELL TECHNOLOGY ACHIEVES CLINICAL MILESTONE
    • GERON SELLS STEM CELL ASSETS
    • PROGENITOR CELL THERAPY, AND HACKENSACK UNIVERSITY MEDICAL CENTER ENTER INTO A CELL PROCESSING AND STORAGE SERVICES AGREEMENT
    • NEW COMPANY APPLIES REGENERATIVE MEDICINE TO CORNEAL TRANSPLANTATION
    • BIOTIME SIGNS DEFINITIVE AGREEMENT WITH GERON REGARDING STEM CELL ASSETS
    • CELLULAR DYNAMICS ANNOUNCES AGREEMENT WITH ASTRAZENECA ON USE OF IPSC-DERIVED HUMAN CELLS IN DRUG DISCOVERY RESEARCH
    • SANFORD-BURNHAM AND INTREXON CORPORATION ESTABLISH COLLABORATION TO ACCELERATE STEM CELL RESEARCH

E. KEY COMPANY PROFILES

  • THE AMERICAS
  • EUROPE
  • ASIA-PACIFIC
  • REST OF WORLD

IV. INDUSTRY COMPANY DATABASE

V. APPENDIX

  • RESEARCH FOCUS
  • DATA ANALYSIS
  • CURRENCY EXCHANGE RATES
  • ABOUT AXIS RESEARCH MIND
  • DISCLAIMER
  • FEEDBACK

LIST OF TABLES AND CHARTS

I. REPORT FOCUS

  • 1. REGENERATIVE MEDICINE THERAPEUTICS COMPANIES BREAKDOWN - %
  • 2. REGENERATIVE MEDICINE CELL & TISSUE BANKS BREAKDOWN - %
  • 3. TISSUE ENGINEERING PRODUCTS CURRENTLY AVAILABLE IN THE MARKET FOR FOLLOWING AREAS
  • 4. ECONOMIC IMPACT OF VARIOUS DISEASES (IN $USD BILLION)
  • 5. MARKETED CELL THERAPIES BY JURISDICTION FOR USA, EUROPE, SOUTH KOREA, JAPAN, ISRAEL, CANADA & NEW ZEALAND
  • 6. LEADING COMMERCIAL CELL THERAPY PRODUCTS OF KEY COMPANIES
  • 7. CELL THERAPY TRIALS BY THERAPEUTIC AREA FOR EARLY TO MID-STAGE (PHASE 1, 1/2, 2) - % BREAKDOWN
  • 8. LIST OF THERAPEUTIC AREAS IDENTIFIED, VECTORS USED AND GENE TYPES TRANSFERRED IN GENE THERAPY CLINICAL TRIALS
  • 9. USA ANNUAL HEALTHCARE COST PER CAPITA BY AGE (IN $USD)
  • 10. HEALTHCARE EXPENSES IN 2009 BY EXPENSE CATEGORY (FROM HEALTH U.S.A, 2011)

II. REGENERATIVE MEDICINE - MARKET BRIEFING

THE AMERICAS

  • 11. REGENERATIVE MEDICINE - THERAPEUTIC AREA MARKET - ORTHOPEDICS, SKIN/INTEGUMENTARY, CARDIOLOGY, NEUROLOGY, UROLOGY AND OTHER FOR THE AMERICAS CURRENT TRENDS, ESTIMATES & FORECASTS - (2013-2019, IN USD$ MILLION)
  • 12. REGENERATIVE MEDICINE - THERAPEUTIC AREA - ORTHOPEDICS, SKIN/INTEGUMENTARY, CARDIOLOGY, NEUROLOGY, UROLOGY AND OTHER - % OF THE AMERICAS MARKET VALUE - (2016-2019)

EUROPE

  • 13. REGENERATIVE MEDICINE - THERAPEUTIC AREA MARKET - ORTHOPEDICS, SKIN/INTEGUMENTARY, CARDIOLOGY, NEUROLOGY, UROLOGY AND OTHER FOR EUROPE CURRENT TRENDS, ESTIMATES & FORECASTS - (2013-2019, IN USD$ MILLION)
  • 14. REGENERATIVE MEDICINE - THERAPEUTIC AREA - ORTHOPEDICS, SKIN/INTEGUMENTARY, CARDIOLOGY, NEUROLOGY, UROLOGY AND OTHER - % OF EUROPEAN MARKET VALUE - (2016-2019)

ASIA-PACIFIC

  • 15. REGENERATIVE MEDICINE - THERAPEUTIC AREA MARKET - ORTHOPEDICS, SKIN/INTEGUMENTARY, CARDIOLOGY, NEUROLOGY, UROLOGY AND OTHER FOR ASIA-PACIFIC CURRENT TRENDS, ESTIMATES & FORECASTS - (2013-2019, IN USD$ MILLION)
  • 16. REGENERATIVE MEDICINE - THERAPEUTIC AREA - ORTHOPEDICS, SKIN/INTEGUMENTARY, CARDIOLOGY, NEUROLOGY, UROLOGY AND OTHER - % OF ASIA-PACIFIC MARKET VALUE - (2016-2019)

REST OF WORLD

  • 17. REGENERATIVE MEDICINE - THERAPEUTIC AREA MARKET - ORTHOPEDICS, SKIN/INTEGUMENTARY, CARDIOLOGY, NEUROLOGY, UROLOGY AND OTHER FOR REST OF WORLD CURRENT TRENDS, ESTIMATES & FORECASTS - (2013-2019, IN USD$ MILLION)
  • 18. REGENERATIVE MEDICINE - THERAPEUTIC AREA - ORTHOPEDICS, SKIN/INTEGUMENTARY, CARDIOLOGY, NEUROLOGY, UROLOGY AND OTHER - % OF REST OF WORLD MARKET VALUE - (2016-2019)

II. MARKET ANALYSIS

  • 19. GLOBAL REGENERATIVE MEDICINE - SEGMENTATION BY THERAPEUTIC AREAS

REGENERATIVE MEDICINE - GLOBAL

  • 20. REGENERATIVE MEDICINE MARKET - GLOBAL CURRENT TRENDS, ESTIMATES & FORECASTS - (2013-2019, IN USD$ MILLION)
  • 21. REGENERATIVE MEDICINE - GEOGRAPHIC REGION CURRENT TRENDS, ESTIMATES & FORECASTS FOR THE AMERICAS, EUROPE, ASIA-PACIFIC AND REST OF WORLD - (2013-2019, IN USD$ MILLION)
  • 22. REGENERATIVE MEDICINE - % OF THE AMERICAS, EUROPE, ASIA-PACIFIC AND REST OF WORLD MARKET VALUE - (2016-2019)

REGENERATIVE MEDICINE - BY GEOGRAPHY

THE AMERICAS

  • 23. REGENERATIVE MEDICINE - USA, CANADA, BRAZIL AND REST OF THE AMERICAS - (2013-2019, IN USD$ MILLION)
  • 24. REGENERATIVE MEDICINE - % OF USA, CANADA, BRAZIL AND REST OF THE AMERICAS MARKET VALUE - (2016-2019)

EUROPE

  • 25. REGENERATIVE MEDICINE - GERMANY, UNITED KINGDOM, FRANCE, SWITZERLAND, SPAIN, THE NETHERLANDS, RUSSIA AND REST OF EUROPE - (2013-2019, IN USD$ MILLION)
  • 26. REGENERATIVE MEDICINE - % OF GERMANY, UNITED KINGDOM, FRANCE, SWITZERLAND, SPAIN, THE NETHERLANDS, RUSSIA AND REST OF EUROPE MARKET VALUE - (2016-2019)

ASIA-PACIFIC

  • 27. REGENERATIVE MEDICINE - JAPAN, SOUTH KOREA, AUSTRALIA, CHINA, INDIA AND REST OF ASIA-PACIFIC - (2013-2019, IN USD$ MILLION)
  • 28. REGENERATIVE MEDICINE - % OF JAPAN, SOUTH KOREA, AUSTRALIA, CHINA, INDIA AND REST OF ASIA-PACIFIC MARKET VALUE - (2016-2019)

REST OF WORLD

  • 29. REGENERATIVE MEDICINE - AFRICA AND MIDDLE EAST - (2013-2019, IN USD$ MILLION)
  • 30. REGENERATIVE MEDICINE - % OF AFRICA AND MIDDLE EAST MARKET VALUE - (2016-2019)

REGENERATIVE MEDICINE - BY THERAPEUTIC AREA

  • 31. REGENERATIVE MEDICINE - THERAPEUTIC AREA MARKET - ORTHOPEDICS, SKIN/INTEGUMENTARY, CARDIOLOGY, NEUROLOGY, UROLOGY AND OTHER FOR GLOBAL CURRENT TRENDS, ESTIMATES & FORECASTS - (2013-2019, IN USD$ MILLION)
  • 32. REGENERATIVE MEDICINE - THERAPEUTIC AREA - ORTHOPEDICS, SKIN/INTEGUMENTARY, CARDIOLOGY, NEUROLOGY, UROLOGY AND OTHER - % OF GLOBAL MARKET VALUE - (2016-2019)

REGENERATIVE MEDICINE - THERAPEUTIC AREA - BY GEOGRAPHY

ORTHOPEDICS

  • 33. ORTHOPEDICS MARKET - GEOGRAPHIC REGION CURRENT TRENDS, ESTIMATES & FORECASTS FOR THE AMERICAS, EUROPE, ASIA-PACIFIC AND REST OF WORLD - (2013-2019, IN USD$ MILLION)
  • 34. ORTHOPEDICS - % OF THE AMERICAS, EUROPE, ASIA-PACIFIC AND REST OF WORLD MARKET VALUE - (2016-2019)

THE AMERICAS

  • 35. ORTHOPEDICS MARKET - USA, CANADA, BRAZIL AND REST OF THE AMERICAS - (2013-2019, IN USD$ MILLION)
  • 36. ORTHOPEDICS - % OF USA, CANADA, BRAZIL AND REST OF THE AMERICAS MARKET VALUE - (2016-2019)

EUROPE

  • 37. ORTHOPEDICS MARKET - GERMANY, UNITED KINGDOM, FRANCE, SWITZERLAND, SPAIN, THE NETHERLANDS, RUSSIA AND REST OF EUROPE - (2013-2019, IN USD$ MILLION)
  • 38. ORTHOPEDICS - % OF GERMANY, UNITED KINGDOM, FRANCE, SWITZERLAND, SPAIN, THE NETHERLANDS, RUSSIA AND REST OF EUROPE MARKET VALUE - (2016-2019)

ASIA-PACIFIC

  • 39. ORTHOPEDICS MARKET - JAPAN, SOUTH KOREA, AUSTRALIA, CHINA, INDIA AND REST OF ASIA-PACIFIC - (2013-2019, IN USD$ MILLION)
  • 40. ORTHOPEDICS - % OF JAPAN, SOUTH KOREA, AUSTRALIA, CHINA, INDIA AND REST OF ASIA-PACIFIC MARKET VALUE - (2016-2019)

REST OF WORLD

  • 41. ORTHOPEDICS MARKET - AFRICA AND MIDDLE EAST - (2013-2019, IN USD$ MILLION)
  • 42. ORTHOPEDICS - % OF AFRICA AND MIDDLE EAST MARKET VALUE - (2016-2019)

SKIN/INTEGUMENTARY

  • 43. SKIN/INTEGUMENTARY MARKET - GEOGRAPHIC REGION CURRENT TRENDS, ESTIMATES & FORECASTS FOR THE AMERICAS, EUROPE, ASIA-PACIFIC AND REST OF WORLD - (2013-2019, IN USD$ MILLION)
  • 44. SKIN/INTEGUMENTARY - % OF THE AMERICAS, EUROPE, ASIA-PACIFIC AND REST OF WORLD MARKET VALUE - (2016-2019)

THE AMERICAS

  • 45. SKIN/INTEGUMENTARY MARKET - USA, CANADA, BRAZIL AND REST OF THE AMERICAS - (2013-2019, IN USD$ MILLION)
  • 46. SKIN/INTEGUMENTARY - % OF USA, CANADA, BRAZIL AND REST OF THE AMERICAS MARKET VALUE - (2016-2019)

EUROPE

  • 47. SKIN/INTEGUMENTARY MARKET - GERMANY, UNITED KINGDOM, FRANCE, SWITZERLAND, SPAIN, THE NETHERLANDS, RUSSIA AND REST OF EUROPE - (2013-2019, IN USD$ MILLION)
  • 48. SKIN/INTEGUMENTARY - % OF GERMANY, UNITED KINGDOM, FRANCE, SWITZERLAND, SPAIN, THE NETHERLANDS, RUSSIA AND REST OF EUROPE MARKET VALUE - (2016-2019)

ASIA-PACIFIC

  • 49. SKIN/INTEGUMENTARY MARKET - JAPAN, SOUTH KOREA, AUSTRALIA, CHINA, INDIA AND REST OF ASIA-PACIFIC - (2013-2019, IN USD$ MILLION)
  • 50. SKIN/INTEGUMENTARY - % OF JAPAN, SOUTH KOREA, AUSTRALIA, CHINA, INDIA AND REST OF ASIA-PACIFIC MARKET VALUE - (2016-2019)

REST OF WORLD

  • 51. SKIN/INTEGUMENTARY MARKET - AFRICA AND MIDDLE EAST - (2013-2019, IN USD$ MILLION)
  • 52. SKIN/INTEGUMENTARY - % OF AFRICA AND MIDDLE EAST MARKET VALUE - (2016-2019)

CARDIOLOGY

  • 53. CARDIOLOGY MARKET - GEOGRAPHIC REGION CURRENT TRENDS, ESTIMATES & FORECASTS FOR THE AMERICAS, EUROPE, ASIA-PACIFIC AND REST OF WORLD - (2013-2019, IN USD$ MILLION)
  • 54. CARDIOLOGY - % OF THE AMERICAS, EUROPE, ASIA-PACIFIC AND REST OF WORLD MARKET VALUE - (2016-2019)

THE AMERICAS

  • 55. CARDIOLOGY MARKET - USA, CANADA, BRAZIL AND REST OF THE AMERICAS - (2013-2019, IN USD$ MILLION)
  • 56. CARDIOLOGY - % OF USA, CANADA, BRAZIL AND REST OF THE AMERICAS MARKET VALUE - (2016-2019)

EUROPE

  • 57. CARDIOLOGY MARKET - GERMANY, UNITED KINGDOM, FRANCE, SWITZERLAND, SPAIN, THE NETHERLANDS, RUSSIA AND REST OF EUROPE - (2013-2019, IN USD$ MILLION)
  • 58. CARDIOLOGY - % OF GERMANY, UNITED KINGDOM, FRANCE, SWITZERLAND, SPAIN, THE NETHERLANDS, RUSSIA AND REST OF EUROPE MARKET VALUE - (2016-2019)

ASIA-PACIFIC

  • 59. CARDIOLOGY MARKET - JAPAN, SOUTH KOREA, AUSTRALIA, CHINA, INDIA AND REST OF ASIA-PACIFIC - (2013-2019, IN USD$ MILLION)
  • 60. CARDIOLOGY - % OF JAPAN, SOUTH KOREA, AUSTRALIA, CHINA, INDIA AND REST OF ASIA-PACIFIC MARKET VALUE - (2016-2019)

REST OF WORLD

  • 61. CARDIOLOGY MARKET - AFRICA AND MIDDLE EAST - (2013-2019, IN USD$ MILLION)
  • 62. CARDIOLOGY - % OF AFRICA AND MIDDLE EAST MARKET VALUE - (2016-2019)

NEUROLOGY

  • 63. NEUROLOGY MARKET - GEOGRAPHIC REGION CURRENT TRENDS, ESTIMATES & FORECASTS FOR THE AMERICAS, EUROPE, ASIA-PACIFIC AND REST OF WORLD - (2013-2019, IN USD$ MILLION)
  • 64. NEUROLOGY - % OF THE AMERICAS, EUROPE, ASIA-PACIFIC AND REST OF WORLD MARKET VALUE - (2016-2019)

THE AMERICAS

  • 65. NEUROLOGY MARKET - USA, CANADA, BRAZIL AND REST OF THE AMERICAS - (2013-2019, IN USD$ MILLION)
  • 66. NEUROLOGY - % OF USA, CANADA, BRAZIL AND REST OF THE AMERICAS MARKET VALUE - (2016-2019)

EUROPE

  • 67. NEUROLOGY MARKET - GERMANY, UNITED KINGDOM, FRANCE, SWITZERLAND, SPAIN, THE NETHERLANDS, RUSSIA AND REST OF EUROPE - (2013-2019, IN USD$ MILLION)
  • 68. NEUROLOGY - % OF GERMANY, UNITED KINGDOM, FRANCE, SWITZERLAND, SPAIN, THE NETHERLANDS, RUSSIA AND REST OF EUROPE MARKET VALUE - (2016-2019)

ASIA-PACIFIC

  • 69. NEUROLOGY MARKET - JAPAN, SOUTH KOREA, AUSTRALIA, CHINA, INDIA AND REST OF ASIA-PACIFIC - (2013-2019, IN USD$ MILLION)
  • 70. NEUROLOGY - % OF JAPAN, SOUTH KOREA, AUSTRALIA, CHINA, INDIA AND REST OF ASIA-PACIFIC MARKET VALUE - (2016-2019)

REST OF WORLD

  • 71. NEUROLOGY MARKET - AFRICA AND MIDDLE EAST - (2013-2019, IN USD$ MILLION)
  • 72. NEUROLOGY - % OF AFRICA AND MIDDLE EAST MARKET VALUE - (2016-2019)

UROLOGY

  • 73. UROLOGY MARKET - GEOGRAPHIC REGION CURRENT TRENDS, ESTIMATES & FORECASTS FOR THE AMERICAS, EUROPE, ASIA-PACIFIC AND REST OF WORLD - (2013-2019, IN USD$ MILLION)
  • 74. UROLOGY - % OF THE AMERICAS, EUROPE, ASIA-PACIFIC AND REST OF WORLD MARKET VALUE - (2016-2019)

THE AMERICAS

  • 75. UROLOGY MARKET - USA, CANADA, BRAZIL AND REST OF THE AMERICAS - (2013-2019, IN USD$ MILLION)
  • 76. UROLOGY - % OF USA, CANADA, BRAZIL AND REST OF THE AMERICAS MARKET VALUE - (2016-2019)

EUROPE

  • 77. UROLOGY MARKET - GERMANY, UNITED KINGDOM, FRANCE, SWITZERLAND, SPAIN, THE NETHERLANDS, RUSSIA AND REST OF EUROPE - (2013-2019, IN USD$ MILLION)
  • 78. UROLOGY - % OF GERMANY, UNITED KINGDOM, FRANCE, SWITZERLAND, SPAIN, THE NETHERLANDS, RUSSIA AND REST OF EUROPE MARKET VALUE - (2016-2019)

ASIA-PACIFIC

  • 79. UROLOGY MARKET - JAPAN, SOUTH KOREA, AUSTRALIA, CHINA, INDIA AND REST OF ASIA-PACIFIC - (2013-2019, IN USD$ MILLION)
  • 80. UROLOGY - % OF JAPAN, SOUTH KOREA, AUSTRALIA, CHINA, INDIA AND REST OF ASIA-PACIFIC MARKET VALUE - (2016-2019)

REST OF WORLD

  • 81. UROLOGY MARKET - AFRICA AND MIDDLE EAST - (2013-2019, IN USD$ MILLION)
  • 82. UROLOGY - % OF AFRICA AND MIDDLE EAST MARKET VALUE - (2016-2019)

OTHER THERAPEUTIC AREAS (REGENERATIVE MEDICINE)

  • 83. OTHER THERAPEUTIC AREAS (REGENERATIVE MEDICINE) MARKET - GEOGRAPHIC REGION CURRENT TRENDS, ESTIMATES & FORECASTS FOR THE AMERICAS, EUROPE, ASIA-PACIFIC AND REST OF WORLD - (2013-2019, IN USD$ MILLION)
  • 84. OTHER THERAPEUTIC AREAS (REGENERATIVE MEDICINE) - % OF THE AMERICAS, EUROPE, ASIA-PACIFIC AND REST OF WORLD MARKET VALUE - (2016-2019)

THE AMERICAS

  • 85. OTHER THERAPEUTIC AREAS (REGENERATIVE MEDICINE) MARKET - USA, CANADA, BRAZIL AND REST OF THE AMERICAS - (2013-2019, IN USD$ MILLION)
  • 86. OTHER THERAPEUTIC AREAS (REGENERATIVE MEDICINE) - % OF USA, CANADA, BRAZIL AND REST OF THE AMERICAS MARKET VALUE - (2016-2019)

EUROPE

  • 87. OTHER THERAPEUTIC AREAS (REGENERATIVE MEDICINE) MARKET - GERMANY, UNITED KINGDOM, FRANCE, SWITZERLAND, SPAIN, THE NETHERLANDS, RUSSIA AND REST OF EUROPE - (2013-2019, IN USD$ MILLION)
  • 88. OTHER THERAPEUTIC AREAS (REGENERATIVE MEDICINE) - % OF GERMANY, UNITED KINGDOM, FRANCE, SWITZERLAND, SPAIN, THE NETHERLANDS, RUSSIA AND REST OF EUROPE MARKET VALUE - (2016-2019)

ASIA-PACIFIC

  • 89. OTHER THERAPEUTIC AREAS (REGENERATIVE MEDICINE) MARKET - JAPAN, SOUTH KOREA, AUSTRALIA, CHINA, INDIA AND REST OF ASIA-PACIFIC - (2013-2019, IN USD$ MILLION)
  • 90. OTHER THERAPEUTIC AREAS (REGENERATIVE MEDICINE) - % OF JAPAN, SOUTH KOREA, AUSTRALIA, CHINA, INDIA AND REST OF ASIA-PACIFIC MARKET VALUE - (2016-2019)

REST OF WORLD

  • 91. OTHER THERAPEUTIC AREAS (REGENERATIVE MEDICINE) MARKET - AFRICA AND MIDDLE EAST - (2013-2019, IN USD$ MILLION)
  • 92. OTHER THERAPEUTIC AREAS (REGENERATIVE MEDICINE) - % OF AFRICA AND MIDDLE EAST MARKET VALUE - (2016-2019)

REGENERATIVE MEDICINE - BIOLOGICAL SUBSTITUTES - BY TYPE

  • 93. REGENERATIVE MEDICINE - BIOLOGICAL SUBSTITUTES MARKET - CELLS AND -BIOMATERIALS, BIOMOLECULES, MANUFACTURING FACTORS AND OTHER FOR GLOBAL CURRENT TRENDS, ESTIMATES & FORECASTS - (2013-2019, IN USD$ MILLION)
  • 94. REGENERATIVE MEDICINE - BIOLOGICAL SUBSTITUTES - CELLS AND BIOMATERIALS, BIOMOLECULES, MANUFACTURING FACTORS AND OTHER - % OF GLOBAL MARKET VALUE - (2016-2019)

B. GROWTH RATE ANALYSIS

  • 95. REGENERATIVE MEDICINE MARKET - GEOGRAPHIC REGION - % GROWTH RATE FORECASTS - (2013-2019)
  • 96. REGENERATIVE MEDICINE - BY THERAPEUTIC AREA - % GROWTH RATE FORECASTS FOR ORTHOPEDICS, SKIN/INTEGUMENTARY, CARDIOLOGY, NEUROLOGY, UROLOGY AND OTHER - (2013-2019)

C. INVESTMENT FOCUS

  • 97. REGENERATIVE MEDICINE - FORECASTED CAGR% - 2013-2019 - TOP 8 COUNTRIES - USA, BRAZIL, SPAIN, RUSSIA, CHINA, JAPAN, SOUTH KOREA AND INDIA
  • 98. REGENERATIVE MEDICINE - THERAPEUTIC AREA - ORTHOPEDICS, SKIN/INTEGUMENTARY, CARDIOLOGY, NEUROLOGY, UROLOGY AND OTHER - FORECASTED CAGR% - VALUE - 2012-2018 - TOP 8 COUNTRIES - USA, JAPAN, CHINA, FRANCE, INDIA, SOUTH KOREA, RUSSIA AND BRAZIL

III. INDUSTRY OVERVIEW

  • 99. WORLDWIDE KEY PLAYERS INTO REGENERATIVE MEDICINE INDUSTRY THAT PROJECT IMPROVED MARKET ACTIVITIES IN THE NEAR FUTURE

KEY COMPANY PROFILES

THE AMERICAS

  • CELL2B (USA)
  • ANGIOCRINE BIOSCIENCE (USA)
  • PLATELET BIOGENESIS (USA)
  • BIOMATRICA, INC (USA)
  • ATHERSYS, INC. (USA)
  • CELLULAR DYNAMICS INTERNATIONAL, INC. (USA)
  • TENGION INC (USA)
  • VERICEL CORPORATION (USA)
  • WRIGHT MEDICAL TECHNOLOGY (USA)
  • TISSUEGENE, INC. (USA)
  • SHIRE REGENERATIVE MEDICINE (USA)
  • REGEN BIOPHARMA (BIO-MATRIX SCIENTIFIC GROUP) (USA)
  • DSM BIOMEDICAL (USA)
  • HARVARD APPARATUS REGENERATIVE TECHNOLOGY (USA)

EUROPE

  • CELLSERVE GMBH (GERMANY)
  • TRAKCEL LTD (UNITED KINGDOM)
  • CRISPR THERAPEUTICS (SWITZERLAND)

ASIA-PACIFIC

  • CYTORI THERAPEUTICS INC (JAPAN)
  • CYFUSE BIOMEDICAL KK (JAPAN)
  • REGENOVO BIOTECHNOLOGY (CHINA)
  • CYNATA THERAPEUTICS LIMITED (AUSTRALIA)
Back to Top